CYTO NK-102 / CytoImmune, City of Hope - LARVOL DELTA

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Sep 2025 ➔ Jun 2026 | Trial primary completion date: Sep 2025 ➔ Jun 2026

Checkpoint inhibition • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: City of Hope Medical Center | Recruiting ➔ Active, not recruiting | N=21 ➔ 6

Checkpoint inhibition • Enrollment change • Enrollment closed • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

CytoImmune Therapeutics Expands Phase 1 Trial of CYTO-102 (PRWeb) - "CytoImmune Therapeutics announces today a significant extension of its ongoing Phase 1 clinical trial evaluating CYTO-102, now encompassing an additional study site at the Chan Soon-Shiong Institute for Medicine (CSSIFM) in El Segundo, CA. In a supply agreement, Roche has committed to supplying its anti-PD-L1 checkpoint inhibitor, atezolizumab, for use in conjunction with CYTO-102 in this expanded trial....CYTO-102 is being assessed as both a monotherapy and in combination with Tecentriq in patients with relapsed/refractory non-small cell lung cancer (NSCLC). The study enrolled the first 6 patients at City of Hope and will now enroll an additional 18 patients at CSSIFM."

Clinical protocol • Enrollment status • Licensing / partnership • Non Small Cell Lung Cancer

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jan 2025 ➔ Sep 2025 | Trial primary completion date: Jan 2025 ➔ Sep 2025

Checkpoint inhibition • Trial completion date • Trial primary completion date • Immune Modulation • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

CytoImmune Therapeutics to Present Preclinical Data Highlighting Potential of Novel TRACK-NK Cells to Selectively Target and Kill Hematologic and Solid Tumor Cancer Cells (Businesswire) - "CytoImmune Therapeutics...announced new preclinical data highlighting the potential of the company’s tumor-reactive NK (TRACK-NK) cell program, CYTO-102...The data are being presented today during a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held November 10-13, 2022, virtually and in Boston...Findings showed: TRACK-NK (CYTO-102) cells led to serial killing of both hematologic tumor cells (lymphoma) and solid tumor cells (NSCLC) in vitro. Further, when combined with tumor antigen directed monoclonal antibodies, TRACK-NK (CYTO-102) cells led to enhanced serial killing and conversion of an NK-insensitive cell line to sensitive in vitro. TRACK-NK (CYTO-102) cells effectively 'cycle' the expression of CD16 and as is common for serial killers, expression is rapidly restored following resting or cryopreservation of the cells."

Preclinical • Oncology • Solid Tumor

CytoImmune Therapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Trial Evaluating a Novel Off-the-Shelf Engineered Natural Killer Cellular Therapy for the Treatment of Non-Small Cell Lung Cancer (Businesswire) - "CytoImmune Therapeutics...announced that the first patient has been dosed in a Phase 1 clinical trial evaluating CYTO-102, a novel cellular therapy consisting of PD-L1-positive tumor-reactive TRACK-NKTM cells. The trial is assessing CYTO-102 as a monotherapy and in combination with atezolizumab in patients with relapsed/refractory non-small cell lung cancer (NSCLC)."

Trial status • Lung Cancer • Non Small Cell Lung Cancer • Oncology

CytoImmune Presents New Preclinical Data Demonstrating Potential of its Novel, Off-the-Shelf Natural Killer Cell-Based Therapies for the Treatment of Hematologic and Solid Tumor Cancers at AACR (Businesswire) - "CytoImmune Therapeutics...announced new preclinical data supporting the therapeutic potential of its CYTO-102 and CYTO-201 programs as treatments for patients with cancer....The data are being presented at the American Association for Cancer Research (AACR) Annual Meeting....Significant cytotoxicity against a human NSCLC cell line when compared to NK cells without expression of sIL-15, NK cells without expression PD-L1, or NK cells without expression of both....Reduced tumor burden and prolonged survival in an aggressive AML mouse model when compared to cells only expressing IL-15 or to the control group."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

City of Hope to Present Late-Breaking and Clinical Trial Data at AACR: Cell Therapy and Preventive Medicine (Businesswire) - "Researchers at City of Hope...will present late-breaking and clinical trial findings at this year’s American Association for Cancer Research Annual Meeting....Jianhua Yu, Michael Caligiuri and colleagues have developed a new cell therapy approach using natural killer cells that, in lab models, induced a greater response against acute myeloid leukemia (AML) and lengthened the survival of mice with AML without damaging healthy blood stem cells....When tested in mice transplanted with human non-small cell lung cancer, the innovative cell therapy City of Hope developed worked better than un-engineered natural killer cells and did not appear to affect body weight, liver or kidney function, or blood counts....The research team treated mice with brain tumors first with the oncolytic virus, then with cell therapy, and showed that together the two treatments did not cause any side effects."

Late-breaking abstract • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

CytoImmune to Present New Preclinical Data Highlighting Potential of Novel TRACK-NK Cell Therapies as Treatments for both Solid Tumors and Hematologic Malignancies (Businesswire) - "CytoImmune Therapeutics...announced that the company will present preclinical data from its FLT3 CAR-NK cell program for acute myeloid leukemia and its TRACK-NK™ program for non-small cell lung cancer at the American Association for Cancer Research (AACR) Annual Meeting....Data to be presented during late breaker poster sessions at 2022 AACR Annual Meeting."

Late-breaking abstract • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor